EMA signs off on Sanofi and GSK's BAR­DA-fund­ed Covid boost­er shot

The Eu­ro­pean Med­i­cines Agency on Thurs­day of­fered a pos­i­tive rec­om­men­da­tion for the first pro­tein-based ad­ju­vant­ed Covid-19 boost­er in Eu­rope, de­vel­oped by Sanofi and GSK.

The BAR­DA-fund­ed vac­cine, known as Vid­Pre­vtyn Be­ta, con­tains a ver­sion of the spike pro­tein found on the sur­face of the Be­ta vari­ant of the coro­n­avirus, and an ad­ju­vant to strength­en the im­mune re­sponse.

The EMA’s hu­man med­i­cines com­mit­tee said Thurs­day that there are suf­fi­cient­ly ro­bust da­ta on the qual­i­ty, safe­ty and im­muno­genic­i­ty of the vac­cine to rec­om­mend its mar­ket­ing au­tho­riza­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.